Wiederanstieg der Januskinaseinhibitor-Neuverordnungen

Following the decline in JAKi prescriptions due to European Medicines Agency safety recommendations, a renewed increase has been observed. Since then, JAKi have been predominantly used in later treatment lines, indicating a more differentiated approach to this drug class.